Compare Heron Therapeutics Inc (HRTX) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Phillips 66 — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Phillips 66 trades at $283 (market cap $112.36B). The key difference: Phillips 66 is far larger — about 1652.1× Heron Therapeutics Inc's market cap, and Phillips 66 pays a 1.8% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Phillips 66 for 62 Days on average.
| HRTX | PSX | |
|---|---|---|
Market Cap | $68.01M | $112.36B |
Volume | 1,891,941 | 2,374,751 |
Sector | Health | Energy |
52-Week High | $1.49 | $281.60 |
52-Week Low | $0.27 | $126.76 |
Typical Hold Time | 35 Days | 62 Days |
Enterprise Value | $174.75M | $128.83B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Phillips 66 (PSX) trades at $271.62, up 0.68% with a bullish technical outlook near its 52-week high. The stock shows strong profitability with 24.02% ROE and 4.66% net margin, supported by three consecutive earnings beats. Recent news highlights structural refining advantages and AI implementation for operational efficiency. Current valuation metrics include a P/E of 16.07 and P/S of 0.75, suggesting reasonable pricing relative to peers.
PSX presents a compelling investment case with analyst consensus at Buy (54% rating) and $279 price target, though revenue declines from 2022-2025 pose concerns. Key risks include diesel export policy uncertainty and refining margin volatility. The company's debt reduction progress and projected 2026 earnings recovery to $7.1B support upside potential if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
